Related Experiment Video
Updated: May 18, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Novel oral anticoagulants in acute coronary syndrome
Charis Costopoulos1, Maria Niespialowska-Steuden, Neville Kukreja
1E&N Hertfordshire NHS Trust, UK.
Insights
Novel oral anticoagulants targeting thrombin pathways offer new hope for reducing recurrent ischemic events in acute coronary syndrome (ACS) patients. This review examines their mechanisms, risks, benefits, and clinical evidence for improved cardiovascular event prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Thrombosis Research
Background:
- Coronary artery disease (CAD) is a global health crisis, with acute coronary syndrome (ACS) being a major cause of hospitalization.
- Despite advances in anti-platelet, anticoagulant therapy, and revascularization, recurrent ischemic events remain a significant challenge for ACS patients.
Purpose of the Study:
- To critically review novel oral agents targeting thrombin-mediated pathways for preventing coronary thrombosis in ACS.
- To compare the mechanisms of action, risks, benefits, and clinical evidence of these new therapies.
Main Methods:
- Literature review of clinical evidence for novel oral anticoagulants in ACS management.
- Comparative analysis of direct Factor Xa inhibitors, direct thrombin inhibitors, and PAR-1 antagonists.
Main Results:
- Novel oral agents, including direct Xa inhibitors (apixaban, rivaroxaban, darexaban), direct thrombin inhibitors (dabigatran), and PAR-1 antagonists (vorapaxar, atopaxar), target specific pathways in thrombosis.
- These agents present a range of risks and benefits that require careful consideration in clinical practice.
- Clinical evidence supports their role in reducing future cardiovascular events for selected ACS patients.
Conclusions:
- Novel oral anticoagulants represent a significant advancement in managing ACS by targeting thrombin pathways.
- A thorough understanding of their comparative profiles is essential for optimizing patient outcomes and reducing recurrent ischemic events.
- Further research and clinical experience will refine the use of these agents in ACS management.
Abstract:
Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide with a prevalence that has now reached pandemic levels as a consequence of the rapid modernization of the developing world. Its presentation as an acute coronary syndrome (ACS) is a frequent reason for hospital admission and of profound implications for personal, societal and global health. Despite improvements in the management of ACS with anti-platelet and anticoagulant therapy and revascularization techniques, many patients continue to suffer recurrent ischemic events. The need to reduce future cardiovascular events has led to the development of novel therapies to prevent coronary thrombosis, targeting thrombin-mediated pathways. These include direct Xa inhibitors (apixaban, rivaroxaban and darexaban), direct thrombin inhibitors (dabigatran) and PAR 1 antagonists (vorapaxar and atopaxar). This article critically reviews the comparative mechanisms of action, the risks and benefits, together with the clinical evidence base for the use of these novel oral agents in the management of ACS patients.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Acute Coronary Syndrome V: Nursing Management